Read More Pharma Industry News FDA clears GenEditBio to begin human testing of GEB-101, a first-in-class genome-editing therapy for TGFBI corneal dystrophy Find out how GenEditBio's GEB-101 genome-editing therapy just cleared FDA to begin trials for TGFBI corneal dystrophy. Could it redefine in vivo editing? byVenkateshJanuary 7, 2026